Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.

Wöll E, Thaler J, Keil F, Gruenberger B, Hejna M, Eisterer W, Fridrik MA, Ulmer H, Trommet V, Huemer F, Weiss L, Greil R.

Anticancer Res. 2017 Oct;37(10):5553-5558.

PMID:
28982869
2.

The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance.

Alidzanovic L, Starlinger P, Schauer D, Maier T, Feldman A, Buchberger E, Stift J, Koeck U, Pop L, Gruenberger B, Gruenberger T, Brostjan C.

Oncotarget. 2016 Aug 30;7(35):57197-57212. doi: 10.18632/oncotarget.11084.

3.

Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response.

Schauer D, Starlinger P, Alidzanovic L, Zajc P, Maier T, Feldman A, Padickakudy R, Buchberger E, Elleder V, Spittler A, Stift J, Pop L, Gruenberger B, Gruenberger T, Brostjan C.

Oncoimmunology. 2016 Mar 22;5(6):e1160185. doi: 10.1080/2162402X.2016.1160185. eCollection 2016 Jun.

4.

Treatment sequence of synchronously (liver) metastasized colon cancer.

Gruenberger T, Beets G, Van Laethem JL, Rougier P, Cervantes A, Douillard JY, Figueras J, Gruenberger B, Haller DG, Labianca R, Maleux G, Roth A, Ducreux M, Schmiegel W, Seufferlein T, Van Cutsem E.

Dig Liver Dis. 2016 Oct;48(10):1119-23. doi: 10.1016/j.dld.2016.06.009. Epub 2016 Jun 17. Review.

PMID:
27375207
5.

Plasma thrombospondin 1 as a predictor of postoperative liver dysfunction.

Starlinger P, Haegele S, Wanek D, Zikeli S, Schauer D, Alidzanovic L, Fleischmann E, Gruenberger B, Gruenberger T, Brostjan C.

Br J Surg. 2015 Jun;102(7):826-36. doi: 10.1002/bjs.9814. Epub 2015 Apr 13.

PMID:
25871570
6.

Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.

Stremitzer S, Stift J, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T.

Eur J Surg Oncol. 2015 Jul;41(7):868-74. doi: 10.1016/j.ejso.2015.03.223. Epub 2015 Mar 24.

PMID:
25865557
7.

Deficiency in thrombopoietin induction after liver surgery is associated with postoperative liver dysfunction.

Haegele S, Offensperger F, Pereyra D, Lahner E, Assinger A, Fleischmann E, Gruenberger B, Gruenberger T, Brostjan C, Starlinger P.

PLoS One. 2015 Jan 22;10(1):e0116985. doi: 10.1371/journal.pone.0116985. eCollection 2015.

8.

Monocytes with angiogenic potential are selectively induced by liver resection and accumulate near the site of liver regeneration.

Schauer D, Starlinger P, Zajc P, Alidzanovic L, Maier T, Buchberger E, Pop L, Gruenberger B, Gruenberger T, Brostjan C.

BMC Immunol. 2014 Oct 30;15:50. doi: 10.1186/s12865-014-0050-3.

9.

CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.

Stremitzer S, Stift J, Graf A, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T.

Ann Surg Oncol. 2015 Apr;22(4):1315-23. doi: 10.1245/s10434-014-4158-8. Epub 2014 Oct 17.

PMID:
25323471
10.

Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.

Farkouh A, Scheithauer W, Buchner P, Georgopoulos A, Schueller J, Gruenberger B, Czejka M.

Anticancer Res. 2014 Jul;34(7):3669-73.

PMID:
24982385
11.

Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans.

Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, Birner P, Fleischmann E, Gruenberger B, Brostjan C, Gruenberger T.

Hepatology. 2014 Jul;60(1):257-66. doi: 10.1002/hep.26950.

PMID:
24277679
12.

Clinical evidence for thrombospondin-1 as a relevant suppressor of liver regeneration.

Starlinger P, Schauer D, Alidzanovic L, Zikeli S, Gebhardt K, Luf F, Fleischmann E, Perisanidis B, Gruenberger B, Gruenberger T, Brostjan C.

J Hepatol. 2013 May;58(5):1053-4. doi: 10.1016/j.jhep.2012.11.037. Epub 2012 Dec 1. No abstract available.

13.

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab.

Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B, Wrba F, Gruenberger T.

Br J Surg. 2012 Nov;99(11):1575-82. doi: 10.1002/bjs.8909.

PMID:
23027075
14.

Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation.

Starlinger P, Alidzanovic L, Schauer D, Maier T, Nemeth C, Perisanidis B, Tamandl D, Gruenberger B, Gruenberger T, Brostjan C.

Br J Cancer. 2012 Sep 4;107(6):961-6. doi: 10.1038/bjc.2012.342. Epub 2012 Jul 31.

15.

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S, Gruenberger T.

Lancet Oncol. 2010 Dec;11(12):1142-8. doi: 10.1016/S1470-2045(10)70247-3. Epub 2010 Nov 9.

PMID:
21071270
16.

Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.

Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, Gruenberger T.

Ann Surg Oncol. 2011 Feb;18(2):421-30. doi: 10.1245/s10434-010-1317-4. Epub 2010 Sep 16.

PMID:
20844968
17.

Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer.

Czejka M, Gruenberger B, Kiss A, Farkouh A, Schueller J.

Anticancer Res. 2010 Jun;30(6):2355-60.

PMID:
20651393
18.

Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.

Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K, Fleischmann E, Gruenberger T.

Ann Surg. 2010 Jul;252(1):124-30. doi: 10.1097/SLA.0b013e3181deb67f.

PMID:
20562613
19.

Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.

Czejka M, Schueller J, Farkouh A, Gruenberger B, Scheithauer W.

Cancer Chemother Pharmacol. 2011 Mar;67(3):613-9. doi: 10.1007/s00280-010-1363-4. Epub 2010 May 22.

PMID:
20495919
20.

Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes.

Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker K, Gruenberger B, Gruenberger T, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C.

J Thromb Haemost. 2010 Aug;8(8):1809-19. doi: 10.1111/j.1538-7836.2010.03908.x. Epub 2010 May 12.

Supplemental Content

Loading ...
Support Center